Life Study

The primary objective of the LIFE Study is to establish the clinical impact of a PoC-EID for infants and neonates from Mozambique and Tanzania at birth and week 4- 8 weeks, linked with nurse-initiated immediate ART initiation in HIV-infected neonates, versus standard-of-care (SoC) on the primary and secondary endpoints. Combined clinical outcomes will include mortality, morbidity (WHO Stage 2 or above disease, severe infant medical conditions), hospitalization, toxicity (Grade 3 or above laboratory abnormality), poor antiretroviral treatment response (confirmed virological failure, treatment termination or prolonged interruption), or loss to follow up of HIV-infected infants.